House panel clears FDA bills giving more post-market authority

A House subcommittee approved a package of bills to overhaul drug-safety laws and give the FDA additional powers to require studies, limit distribution or order label changes for drugs on the market. The panel also replaced language that would have allowed the health secretary to ban new drug ads on television with a provision allowing the FDA to fine companies $250,000 for showing false or misleading ads directed at consumers.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA